ALK and lung carcinoma: EMT drives acquired resistance to ALK tyrosine kinase inhibitors (ALK-TKIs) in lung cancer cells, while silybin co-exposure re-sensitizes lung cancer cells to ALK-TKIs by targeting the TGF-β/Smad signaling axis [57].